Status:
RECRUITING
Imagery Rescripting as Treatment for Depression
Lead Sponsor:
University of Amsterdam
Collaborating Sponsors:
Academic Center for Trauma and Personality
Conditions:
Major Depressive Disorder
Persistent Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The goal of this multiple baseline case series study is to test Imagery Rescripting in depression. The main question\[s\] it aims to answer are: * does Imagery Rescripting lead to a reduction of depr...
Detailed Description
In a multiple baseline case series study the effectiveness of Imagery Rescripting (ImRs) as a treatment for depression will be tested. 10 patients with a major depressive disorder (MDD) or a persisten...
Eligibility Criteria
Inclusion
- Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5)
- Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.)
- Age 18-65
- Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter)
- Willingness to participate in the study (signed informed consent)
Exclusion
- DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included
- Psychotic disorders (though psychotic features alongside depression will be allowed)
- Organic brain disease
- Intelligence Quotient (IQ) \< 80
- High risk of self-harm or suicide
- Current substance abuse severe level
- Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study)
- Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year
- No other evidence-based treatment of MDD is allowed during the study.
- Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.
Key Trial Info
Start Date :
August 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05976945
Start Date
August 10 2023
End Date
August 1 2027
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Center for Trauma and Personality ACTP
Amsterdam, Netherlands, 1062 XD